C
Christopher A. Langley
Researcher at Aston University
Publications - 62
Citations - 713
Christopher A. Langley is an academic researcher from Aston University. The author has contributed to research in topics: Pharmacy & Pharmacy practice. The author has an hindex of 13, co-authored 61 publications receiving 669 citations.
Papers
More filters
Journal ArticleDOI
The corporatization of community pharmacy: implications for service provision, the public health function, and pharmacy's claims to professional status in the United Kingdom.
TL;DR: A mixed market in community pharmacy may be required to maintain a comprehensive range of pharmacy-based public health services and provide maximum benefit to all patients.
Journal ArticleDOI
An analysis of returned medicines in primary care.
TL;DR: Investigation of the types and amounts of medicines returned to both general practices and associated local community pharmacies indicates that unused medicines impose a significant financial burden on the National Health Service as well as a socialurden on the United Kingdom population.
Book
Pharmaceutical Compounding and Dispensing
TL;DR: This new edition of Pharmaceutical Compounding and Dispensing provides a comprehensive guide to producing extemporaneous formulations safely and effectively.
Journal ArticleDOI
Synthesis and evaluation of 5-arylated 2(5H)-furanones and 2-arylated pyridazin-3(2H)-ones as anti-cancer agents.
Eric Lattmann,Washington Odur Ayuko,Derek Kinchinaton,Christopher A. Langley,Harjit Singh,Leila Karimi,Michael J. Tisdale +6 more
TL;DR: In‐vitro cytotoxicity correlated with an in‐vivo inhibition of tumour growth and the ring expansion of the 5‐membered 2(5H)‐furanone ring system such as 6a into the 6‐ Membered 3(2H)––pyridazone 9b led to an agent with improved antineoplastic properties.
Journal ArticleDOI
Novel anti-bacterials against MRSA:Synthesis of focussed combinatorial libraries of tri-substituted 2(5H)-furanones
Eric Lattmann,Nison Sattayasai,Carl S. Schwalbe,Suwanna Niamsanit,David C. Billington,Pornthip Lattmann,Christopher A. Langley,Harjit Singh,Simon Dunn +8 more
TL;DR: The 3-bromo-4-benzimizazolyl-5-methoxy-2(5H)furanone, Br-A-l, showed an MIC of 8 microg/ml against the multiresistant Staphylococcus aureus (MRSA).